SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a ...

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Tanvi Lodhia’s path to pharma marketing may sound familiar to her peers in the industry: Like many of them, for example, she ...

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...

Argenx (ARGX) announced that Health Canada has issued a notice of compliance authorizing Vyvgart as a monotherapy for the treatment of adult ...

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological ...

Baron International Growth Fund gained 6.04% (Institutional Shares) during the quarter, slightly underperforming its ...

Speaking in Machakos when she hosted a delegation from Habitat for Humanity Kenya for talks on strategic partnership in the ...

Investing.com -- Argenx (EBR:ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...